A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Trial Profile

A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs BMS 986016 (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Feb 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2018.
    • 30 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 28 Nov 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top